Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1034 results
September 2023
-
Media ReleaseNovartis appoints Patrick Horber, M.D., President, International as Marie-France Tschudin, President, Innovative Medicines International and Chief Commercial Officer, steps down from the Executive Committee of NovartisAfter nearly seven years at Novartis and more than four years as a member of the ECN, Ms. Tschudin will pursue her next chapter of leadership outside of Novartis Dr. Horber to drive next phase…
-
Key ReleaseSandoz publishes supplement to Listing Prospectus including Sandoz H1 2023 financial statementsAd hoc announcement pursuant to Art. 53 LRSupplement published by Sandoz ahead of Novartis Extraordinary General Meeting on September 15, 2023H1 results demonstrated continued momentum with strong…
August 2023
-
Media ReleaseNovartis presents new long-term Leqvio® (inclisiran) data demonstrating consistent efficacy and safety beyond six yearsResults from the ORION-8 open-label extension trial show twice-yearly* Leqvio, in addition to statin therapy, provides consistent low-density lipoprotein cholesterol (LDL-C) reduction beyond six…
-
Media ReleaseSandoz completes acquisition of leading antifungal agent Mycamine® from Astellas, reinforcing leading global anti-infectives portfolioSandoz completes acquisition of worldwide brand rights for Mycamine® (micafungin sodium) from Astellas Leading global echinocandin, one of three major antifungal classes, will significantly…
-
Media ReleaseSandoz receives FDA approval for Tyruko® (natalizumab-sztn), first and only FDA-approved biosimilar for relapsing forms of multiple sclerosisBiosimilar Tyruko® approved for all indications of reference medicine, with same dosing and administration schedule Sandoz continues to expand access to much-needed medications for patients…
-
Key ReleaseNovartis issues EGM Invitation and Shareholder Information Brochure. Sandoz publishes Listing Prospectus ahead of proposed Spin-off voteAd hoc announcement pursuant to Art. 53 LR Invitation to Novartis Extraordinary General Meeting on September 15, 2023, and Shareholder Information Brochure issuedSandoz Listing Prospectus…
-
Media ReleaseSandoz announces positive results from Mylight Phase lll study for biosimilar afliberceptMylight study met its primary efficacy endpoint and showed no clinically meaningful differences to reference afliberceptResults offer hope of new affordable option for patients with nAMD, a leading…
-
Media ReleaseNovartis completes acquisition of Chinook TherapeuticsAcquisition of Chinook Therapeutics, a clinical-stage biopharmaceutical company, completed for USD 3.2bn upfrontDeal brings two phase 3 assets in development for IgAN; atrasentan, an oral endothelin…
-
Key ReleaseNovartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticariaAd hoc announcement pursuant to Art. 53 LR The Phase III REMIX-1 and REMIX-2 studies met all primary and secondary endpoints, showing rapid, clinically meaningful improvements across…
July 2023
-
Media ReleaseSandoz receives positive CHMP opinion for multiple sclerosis biosimilar natalizumabIf approved, will be first-of-a-kind biosimilar natalizumab in Europe, for use in all indications of reference biologic Positive CHMP opinion based on evidence from extensive analytical…
-
Media ReleaseSandoz announces plans to build a Biosimilar Technical Development Center in Slovenia to support future growth of biosimilar pipelinePlanned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026New end-to-end drug substance and drug…
-
Key ReleaseNovartis delivers strong sales growth, robust margin expansion and raises guidance. Announces USD 15 billion share buyback and Board endorses Sandoz spin-off¹˒²Ad hoc announcement pursuant to Art. 53 LRQ2 sales grew +9% (cc3, +7% USD) with core operating income growing +17% (cc, +9% USD)Innovative Medicines (IM) sales grew +9% (cc, +7% USD) and core…
Pagination
- ‹ Previous page
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- …
- 87
- › Next page